



COVID-19 Provider Update

Wednesday, February 8, 2022



Population Coverage: As of February 1st

			At least one dose		Fully vaccinated		Additional dose Received	
Age Range	% of Population	CT Population	Number	%	Number	%	Number	%
All ages	100.0%	3,565,287	2,976,121	83.5%	2,652,530	74.4%	1,338,254	37.5%
5+	95.0%	3,383,577	2,975,605	87.9%	2,652,149	78.4%	1,338,153	39.5%
12+	87.0%	3,105,947	2,853,781	91.9%	2,556,649	82.3%	1,337,761	43.1%
16+	82.0%	2,929,347	2,714,175	92.7%	2,430,710	83.0%	1,310,574	44.7%
18+	80.0%	2,837,847	2,635,340	92.9%	2,358,970	83.1%	1,284,588	45.3%
35+	57.0%	2,047,745	1,960,853	95.8%	1,785,934	87.2%	1,073,958	52.4%
45+	45.0%	1,620,604	1,566,766	96.7%	1,436,581	88.6%	917,300	56.6%
55+	32.0%	1,143,699	1,139,269	99.6%	1,046,111	91.5%	710,282	62.1%
65+	18.0%	630,244	637,681	101.2%	583,073	92.5%	420,608	66.7%
75+	8.0%	277,425	271,128	97.7%	247,054	89.1%	174,376	62.9%

Data as reported to CT DPH Immunization Information System (IIS) CT WiZ.

All ages estimate includes 236 people with unknown age

Additional dose includes individuals who have had at least one dose after completion of the a primary COVID-19 vaccine series

Age coverage: Specific age groups

Doses Reported by 2/1/2022

			At least one dose		Fully vaccinated		Additional dose Received	
Age Range	% of Population	CT Population	Number	%	Number	%	Number	%
<5	5.0%	181,710	0	0.0%	0	0.0%	0	0.0%
5-11	8.0%	277,630	121,824	43.9%	95,500	34.4%	392	0.1%
12-15	5.0%	176,600	139,606	79.1%	125,939	71.3%	27,187	15.4%
16-17	3.0%	91,500	78,835	86.2%	71,740	78.4%	25,986	28.4%
18-24	10.0%	342,073	282,729	82.7%	235,573	68.9%	86,430	25.3%
25-34	13.0%	448,029	391,758	87.4%	337,463	75.3%	124,200	27.7%
35-44	12.0%	427,141	394,087	92.3%	349,353	81.8%	156,658	36.7%
45-54	13.0%	476,905	427,497	89.6%	390,470	81.9%	207,018	43.4%
55-64	14.0%	513,455	501,588	97.7%	463,038	90.2%	289,674	56.4%
65-74	10.0%	352,819	366,553	100.0%	336,019	95.2%	246,232	69.8%
75-84	5.0%	186,095	191,379	100.0%	174,854	94.0%	128,223	68.9%
85+	3.0%	91,330	79,749	87.3%	72,200	79.1%	46,153	50.5%
Grand Total		3,565,287	2,975,605	83.5%	2,652,149	74.4%	1,338,153	37.5%

*At least one dose includes individuals who have received one dose of Pfizer, Moderna, or J&J

**Fully vaccinated includes individuals who received one dose of J&J, two doses of Moderna, or two doses of Pfizer.

***Additional dose includes individuals who have had at least one dose after completion of the a primary COVID-19 vaccine series

****516 people with age missing are excluded from this table



COVID-19 Young Pediatric Vaccination Planning Survey

The Department sent an [email](#) to all CoVP providers last Friday to assess readiness and anticipated barriers to vaccinate children under age 5. If you have multiple enrolled provider locations, then please complete a separate survey for each PIN.

If you oversee more than 5 provider PINs (e.g., chain pharmacies), then please email Dph.immunizations@ct.gov with the subject line “Spring 2022 Provider Survey: Young Pediatric Planning” and we will follow up with you directly.

Please complete the survey at the link below by Wednesday, February 9, 2022.

Survey Link: <https://www.surveymonkey.com/r/COVID-19YoungPediPlanning>



COVID-19 Young Pediatric Vaccine Pre-Order

The Centers for Disease Control and Prevention (CDC) has announced the anticipated shipping dates for week 1 of Pfizer's young pediatric product (<5 years). To be eligible to receive vaccine on day one, you must be able to receive a shipment on Monday, February 21 (President's Day). Anyone who orders product but is unable to receive a shipment on Monday, February 21 (President's Day) will have product delivered beginning the following day, Tuesday, February 22. A [dedicated order form](#) is being used for the first week that Pfizer's young pediatric COVID-19 vaccine is available. In future weeks, we will revert to the usual COVID-19 vaccine order form.

For Monday, February 21 delivery, please complete this form by Thursday, February 10 at 9:00 am.

The final deadline for a week 1 delivery (Tuesday 2/22 – Friday 2/25) will be Thursday, February 17 at 9:00 am.

Pfizer-BioNTech COVID-19 Vaccine Products

**PRELIMINARY – SUBJECT TO CHANGE PENDING REGULATORY GUIDANCE AND AUTHORIZATION/APPROVAL;
CDC DOCUMENT – SHARED FOR JURISDICTIONAL PLANNING PURPOSES ONLY**

	Current Products		Future Product
Age Indications ^a	12 years and older	5 through 11 years	6 months through 4 years ^d
Vial Cap Color and Label with Color Border	GRAY 	ORANGE 	MAROON 
Preparation	Do Not Dilute	Dilute Before Use	Dilute Before Use
Amount of Diluent Needed per Vial ^b	Do Not Dilute	1.3 mL	2.2 mL
Dose Volume/Dose	0.3 mL/30 mcg	0.2 mL/10 mcg	0.2 mL/3 mcg
Doses per Vial	6 doses per vial	10 doses per vial (after dilution)	10 doses per vial (after dilution)
Storage Conditions			
ULT Freezer (-90°C to -60°C) ^c	9 months	9 months	9 months
Freezer (-25°C to -15°C)	DO NOT STORE	DO NOT STORE	DO NOT STORE
Refrigerator (2°C to 8°C)	10 weeks	10 weeks	10 weeks
Room Temperature (8°C to 25°C)	12 hours prior to first puncture (including any thaw time)	12 hours prior to first puncture (including any thaw time)	12 hours prior to first puncture (including any thaw time)
After First Puncture (2°C to 25°C)	Discard after 12 hours	Discard after 12 hours	Discard after 12 hours

- FDA's VRBPAC is meeting February 15
- Pending FDA's decision, ACIP will meet shortly thereafter
- Providers may begin vaccinating after CDC officially endorses any ACIP recommendations.

^a Use the appropriate product based on the age of the recipient.

^b Diluent: Sterile 0.9% Sodium Chloride Injection, USP. Do not use bacteriostatic 0.9% Sodium Chloride Injection or any other diluent.

^c Regardless of storage condition, vaccines should not be used after 9 months from the date of manufacture printed on the vial and cartons.

^d The vaccine is currently under emergency use authorization review by the Food and Drug Administration (FDA) for children 6 months through 4 years old.

Pfizer Webinars for Healthcare Providers:

COVID-19 Vaccine Medical Updates and Immunization Site Training

Goal: Educate providers and immunization staff personnel on the proper use of the Pfizer-BioNTech COVID-19 Vaccine

Session topics include:

- Use of each vaccine presentation, including storage, handling, preparation, and administration for:
 - Ages 5 through 11 Years: **DILUTE BEFORE USE/Orange Cap**
 - Ages 12 Years and Older:
 - **DO NOT DILUTE/Gray Cap**
 - **DILUTE BEFORE USE/Purple Cap**
 - **Now includes info on Maroon Cap 6mo – 4yo vaccine!**
- Recent medical updates regarding the vaccine
- An overview of healthcare provider resources
- Question and answer session

These sessions will be **updated** to reflect the latest information and recent changes which will be identified at the start of each session.

To access current and future training sessions, please visit:
<https://www.pfizermedicalinformation.com/en-us/medical-updates>

Date & Time	Password
Attendee link – Wednesday, February 9 – 12pm ET	xmPQNq7JJ32
Attendee link – Thursday, February 10 – 12pm ET	deMyFdVJ465
Attendee link – Tuesday, February 15 – 3pm ET	ZteZvrQ3M25
Attendee link – Wednesday, February 16 – 12pm ET	qhJNeDVr372
Attendee link -Thursday, February 17 – 12pm ET	niX7fg3xTR3
Attendee link – Tuesday, February 22 – 3pm ET	MMeBHKrM326
Attendee link – Wednesday, February 23 – 12pm ET	NgBarUWa228
Attendee link – Thursday, February 24 – 12pm ET	nMfj6BJEy32

ACIP Updates

Interval shortened to 3 months for booster dose for immunocompromised

CDC is updating the [COVID-19 vaccine clinical considerations](#) for immunocompromised individuals, changing the interval for the booster dose to 3 months from 5 months (for both Pfizer and Moderna). **People who are moderately or severely immunocompromised should receive a booster dose at least 3 months after the last (third) dose of an mRNA COVID-19 vaccine.** CDC's web sites should be updated shortly. The slides from the meeting related to this discussion can be found [here](#).

Moderna COVID-19 Vaccine is Approved

Last week, the [FDA approved the Moderna COVID-19 vaccine](#), the second COVID-19 vaccine to gain full approval. The vaccine will now be marketed as "Spikevax" for the prevention of COVID-19 disease in individuals 18 years of age and older. The vaccine also continues to be available under EUA.



Holiday Shipping

COVID-19 vaccine WILL be delivered on President's Day, February 21st. Please be aware of that when ordering. If your office will be closed, please include that in the comments on the ordering portal for orders placed this coming week and reach out to DPH.Immunizations@ct.gov so we can hold your order until after the holiday.

CDC Morbidity and Mortality Weekly Report

Stay informed about COVID-19

Read the latest
reports from
MMWR



bit.ly/MMWR_COVID19

MMWR

- SARS-CoV-2 Infection and Hospitalization Among Adults Aged ≥ 18 Years, by Vaccination Status, Before and During SARS-CoV-2 B.1.1.529 (Omicron) Variant Predominance — Los Angeles County, California, November 7, 2021–January 8, 2022. Link [here](#).
- COVID-19 Vaccination Coverage and Vaccine Confidence by Sexual Orientation and Gender Identity — United States, August 29–October 30, 2021. Link [here](#).
- Notes from the Field: COVID-19 Vaccination Among Persons Living with Diagnosed HIV Infection — New York, October 2021. Link [here](#).
- Effectiveness of Face Mask or Respirator Use in Indoor Public Settings for Prevention of SARS-CoV-2 Infection — California, February–December 2021. Link [here](#).
- Clinical Characteristics and Outcomes Among Adults Hospitalized with Laboratory-Confirmed SARS-CoV-2 Infection During Periods of B.1.617.2 (Delta) and B.1.1.529 (Omicron) Variant Predominance — One Hospital, California, July 15–September 23, 2021, and December 21, 2021–January 27, 2022. Link [here](#).

CDC COCA Call

COVID-19 Updates: What Clinicians Need to Know About Multisystem Inflammatory Syndrome in Children - February 10, 2022, 2:00 PM - 3:00 PM ET

- **Overview:** Multisystem inflammatory syndrome in children (MIS-C) is a rare but severe condition associated with SARS-CoV-2 infection. The Centers for Disease Control and Prevention (CDC) has been actively involved in MIS-C surveillance and research, and development of MIS-C resources to support the public health and healthcare community. During this COCA Call, presenters will discuss CDC's surveillance of MIS-C, updated MIS-C resources for healthcare providers, research that informed those resources, and data related to COVID-19 vaccination and MIS-C.
- https://emergency.cdc.gov/coca/calls/2022/callinfo_021022.asp





CT WiZ/VAMS Update

VaccineFinder (Add Inventory)

CT WiZ Enhancement

Transitioning from VAMS to CT WiZ

Helpdesk and Office Hours

VaccineFinder: Why Maintain Your Inventory Data?

VaccineFinder enables:

- Providers to report inventory as required per the Provider Agreement
- Public to find your clinic with COVID-19 vaccine available (if you display)
- Performance metrics (failure to report inventory can impact vaccine orders and threshold amounts)



- To report inventory for COVID-19 vaccines that are not already listed in your COVID Locating Health Portal account, follow the [Add Vaccine](#) link to add COVID-19 vaccine NDC's to your location.
- Once added, you can report on the number of doses on hand daily for that vaccine.

Quick Tips!

- Ensure depots/hubs are updating inventory.
- Providers no longer participating in COVID-19 vaccination must be zeroed out; old inventory numbers can skew performance metrics.
- Reporting of inventory is required per the COVID-19 Provider Agreement.

Guides for reporting inventory and public display information can be found on the [Provider Resources](#) page. If you need support, please contact CARS_Helpdesk@cdc.gov or 1-833-748-1979.

CT WiZ Enhancement

February 7th release: Enhancement added '**Dose Level Accountability**' for CVP eligibility for each vaccine which will enable clinics to properly document both patient and dose level eligibility according to: [Connecticut's Vaccine Eligibility Criteria](#).

- Clinic's using CT WiZ User Interface/Data Entry:
 - select the '**Patient Level Eligibility**' in the Demographics screen which will populate and default to the **Administer Vaccines** screen. After adding vaccine(s), you can change a vaccine's eligibility at the dose level on this screen if needed.
 - (**COVID-19 vaccine is under 'VO1 Not VFC Eligible'**)
- Clinics onboarded with their EHR: will report the same way as now, as eligibility is currently sent with each dose.

Reminder: CT WiZ is down from 8pm-10pm for these Monthly Releases.



VAMS to CT WiZ Transition Process

Has your VAMS Clinic Transitioned to CT WiZ Yet?

Benefits of CT WiZ:

- the consolidated record available to the provider for clinical decision support
- an official immunization record available to the patient in the Public Portal
- ability to electronically report from your EHR
- managing inventory in one system *if both CVP and CoVP*
- ability to run many reports



If your clinic is using VAMS and wants to transition to CT WiZ to manage inventory and report COVID-19 vaccinations:

- ❖ please [submit a helpdesk ticket](#) with your PIN and expected date of transition
- ❖ DPH will schedule a call to review the [transition process](#) with your clinic

Help Desk Updates

DPH Helpdesk Ticketing System



The screenshot shows the 'Create a ticket' form in the DPH Helpdesk Portal. The form is titled 'Create a ticket' and includes a red asterisk legend indicating required fields. The form fields are as follows:

- What system do you need assistance with?**: A dropdown menu with 'Immunizations (CT WiZ)' selected. A red asterisk is next to the dropdown.
- Select the category:**: A dropdown menu with 'Clinic Administration' selected. A red asterisk is next to the dropdown.
- Select the topic:**: A dropdown menu with 'Select a topic...' selected. A red asterisk is next to the dropdown.
- Select the sub topic:**: A dropdown menu with 'Select a topic...' selected. A red asterisk is next to the dropdown.
- First name of the submitter:**: A text input field.
- Last name of the submitter:**: A text input field.
- Contact phone number:**: A text input field.

The dropdown menu for 'Select the sub topic' is open, showing the following options:

- CT WiZ Inventory Management
- CT WiZ Inventory Training
- CT WiZ is down
- CT WiZ is running slow
- CT WiZ Patient Management

- The ticketing system has been updated to consolidate COVID-19 categories under the same umbrella topic as other immunization related questions.
- Topics for Clinic Administration include:
 - CT WiZ Inventory Management, CT WiZ Inventory Training, CT WiZ is down, CT WiZ is running slow, CT WiZ Patient Management, Enroll/Re-enroll in CVP – CoVP, Report records for DPH review/correction, Report Vaccine Wastage (COVID-19), Update Clinic Information, VAMS Support, VAMS to CT WiZ

CT WiZ / VAMS Office Hours

[CT WiZ/VAMS Live Helpdesk Office Hours](#)

Join Via Microsoft Teams

Tuesdays 9:00am – 10:00am

Join us anytime during office hours to ask a question!

*If you can't join during this time, visit our [webpages](#) for training materials or our DPH Helpdesk to [submit a request](#).

Question and Answers

To ask a question, please raise your hand using the hand icon on your screen, type your question in the chat box or if you are on the phone press *6 to unmute yourself.

If you have additional questions after the meeting, please feel free to email them to DPH.Immunizations@ct.gov

You can fill out a help desk ticket by visiting <https://dph-cthelpdesk.ct.gov/Ticket>